6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Serious O
Infections B-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Neurologic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Malignancies B-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Patients O
with O
Heart B-Not_AE_Candidate
Failure I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Hematologic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
Reactivation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Allergic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Autoimmunity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Immunosuppression B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
5 O
% O
) O
: O
infections O
and O
injection O
site O
reactions O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Amgen O
Inc O
. O
at O
1-800-77-AMGEN O
( O
1-800-772-6436 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Across O
clinical O
studies O
and O
postmarketing O
experience O
, O
the O
most O
serious O
adverse O
reactions O
with O
Enbrel O
were O
infections B-OSE_Labeled_AE
, O
neurologic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
CHF B-OSE_Labeled_AE
, O
and O
hematologic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5 O
) O
] O
. O

The O
most O
common O
adverse O
reactions O
with O
Enbrel O
were O
infections B-OSE_Labeled_AE
and O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reactions O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
predict O
the O
rates O
observed O
in O
clinical O
practice O
. O

Adverse O
Reactions O
in O
Adult O
Patients O
w O
ith O
R O
heumatoid O
A O
rthritis O
, O
Psoriatic O
Arthritis O
, O
Ankylosing O
Spondylitis O
, O
or O
Plaque O
Psoriasis O
The O
data O
described O
below O
reflect O
exposure O
to O
Enbrel O
in O
2219 O
adult O
patients O
with O
RA B-Not_AE_Candidate
followed O
for O
up O
to O
80 O
months O
, O
in O
182 O
patients O
with O
PsA B-Not_AE_Candidate
for O
up O
to O
24 O
months O
, O
in O
138 O
patients O
with O
AS B-Not_AE_Candidate
for O
up O
to O
6 O
months O
, O
and O
in O
1204 O
adult O
patients O
with O
PsO B-Not_AE_Candidate
for O
up O
to O
18 O
months O
. O

In O
controlled O
trials O
, O
the O
proportion O
of O
Enbrel-treated O
patients O
who O
discontinued O
treatment O
due O
to O
adverse O
events O
was O
approximately O
4 O
% O
in O
the O
indications O
studied O
. O

Adverse O
Reactions O
in O
Pediatric O
Patients O
In O
general O
, O
the O
adverse O
reactions O
in O
pediatric O
patients O
were O
similar O
in O
frequency O
and O
type O
as O
those O
seen O
in O
adult O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
, O
and O
Clinical O
Studies O
( O
14.2 O
and O
14.6 O
) O
] O
. O

In O
a O
48-week O
clinical O
study O
in O
211 O
children O
aged O
4 O
to O
17 O
years O
with O
pediatric O
PsO B-Not_AE_Candidate
, O
the O
adverse O
reactions O
reported O
were O
similar O
to O
those O
seen O
in O
previous O
studies O
in O
adults O
with O
PsO B-Not_AE_Candidate
. O

Long-term O
safety O
profile O
for O
up O
to O
264 O
additional O
weeks O
was O
assessed O
in O
an O
open-label O
extension O
study O
and O
no O
new O
safety O
signals O
were O
identified O
. O

In O
open-label O
clinical O
studies O
of O
children O
with O
JIA B-Not_AE_Candidate
, O
adverse O
reactions O
reported O
in O
those O
ages O
2 O
to O
4 O
years O
were O
similar O
to O
adverse O
reactions O
reported O
in O
older O
children O
. O

Infections O
Infections B-OSE_Labeled_AE
, O
including O
viral B-OSE_Labeled_AE
, O
bacterial O
, O
and O
fungal O
infections I-OSE_Labeled_AE
, O
have O
been O
observed O
in O
adult O
and O
pediatric O
patients O
. O

Infections B-OSE_Labeled_AE
have O
been O
noted O
in O
all O
body O
systems O
and O
have O
been O
reported O
in O
patients O
receiving O
Enbrel O
alone O
or O
in O
combination O
with O
other O
immunosuppressive B-NonOSE_AE
agents I-NonOSE_AE
. O

In O
controlled O
portions O
of O
trials O
, O
the O
types O
and O
severity O
of O
infection B-OSE_Labeled_AE
were O
similar O
between O
Enbrel O
and O
the O
respective O
control O
group O
( O
placebo O
or O
MTX O
for O
RA B-Not_AE_Candidate
and O
PsA B-Not_AE_Candidate
patients O
) O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
and O
PsO B-Not_AE_Candidate
patients O
. O

Rates O
of O
infections B-NonOSE_AE
in O
RA B-Not_AE_Candidate
and O
adult O
PsO B-Not_AE_Candidate
patients O
are O
provided O
in O
Table O
3 O
and O
Table O
4 O
, O
respectively O
. O

Infections B-OSE_Labeled_AE
consisted O
primarily O
of O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
and O
influenza B-OSE_Labeled_AE
. O

In O
controlled O
portions O
of O
trials O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
and O
PsO B-Not_AE_Candidate
, O
the O
rates O
of O
serious O
infection B-OSE_Labeled_AE
were O
similar O
( O
0.8 O
% O
in O
placebo O
, O
3.6 O
% O
in O
MTX O
, O
and O
1.4 O
% O
in O
Enbrel/Enbrel O
+ O
MTX-treated O
groups O
) O
. O

In O
clinical O
trials O
in O
rheumatologic O
indications O
, O
serious O
infections B-OSE_Labeled_AE
experienced O
by O
patients O
have O
included O
, O
but O
are O
not O
limited O
to O
, O
pneumonia B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
septic B-OSE_Labeled_AE
arthritis I-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
pyelonephritis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
abscess B-OSE_Labeled_AE
and O
osteomyelitis B-OSE_Labeled_AE
. O

In O
clinical O
trials O
in O
adult O
PsO B-Not_AE_Candidate
patients O
, O
serious O
infections B-OSE_Labeled_AE
experienced O
by O
patients O
have O
included O
, O
but O
are O
not O
limited O
to O
, O
pneumonia B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
abscess B-OSE_Labeled_AE
and O
osteomyelitis B-OSE_Labeled_AE
. O

The O
rate O
of O
serious O
infections B-NonOSE_AE
was O
not O
increased O
in O
open-label O
extension O
trials O
and O
was O
similar O
to O
that O
observed O
in O
Enbrel- O
and O
placebo-treated O
patients O
from O
controlled O
trials O
. O

In O
66 O
global O
clinical O
trials O
of O
17,505 O
patients O
( O
21,015 O
patient-years O
of O
therapy O
) O
, O
tuberculosis B-OSE_Labeled_AE
was O
observed O
in O
approximately O
0.02 O
% O
of O
patients O
. O

In O
17,696 O
patients O
( O
27,169 O
patient-years O
of O
therapy O
) O
from O
38 O
clinical O
trials O
and O
4 O
cohort O
studies O
in O
the O
U.S O
. O
and O
Canada O
, O
tuberculosis B-OSE_Labeled_AE
was O
observed O
in O
approximately O
0.006 O
% O
of O
patients O
. O

These O
studies O
include O
reports O
of O
pulmonary B-OSE_Labeled_AE
and O
extrapulmonary O
tuberculosis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

The O
types O
of O
infections B-OSE_Labeled_AE
reported O
in O
pediatric O
patients O
with O
PsO B-Not_AE_Candidate
and O
JIA B-Not_AE_Candidate
were O
generally O
mild O
and O
consistent O
with O
those O
commonly O
seen O
in O
the O
general O
pediatric O
population O
. O

Two O
JIA B-Not_AE_Candidate
patients O
developed O
varicella B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
and O
signs O
and O
symptoms O
of O
aseptic B-OSE_Labeled_AE
meningitis I-OSE_Labeled_AE
, O
which O
resolved O
without O
sequelae O
. O

Injection O
Site O
Reactions O
In O
placebo-controlled O
trials O
in O
rheumatologic O
indications O
, O
approximately O
37 O
% O
of O
patients O
treated O
with O
Enbrel O
developed O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

In O
controlled O
trials O
in O
patients O
with O
PsO B-Not_AE_Candidate
, O
15 O
% O
of O
adult O
patients O
and O
7 O
% O
of O
pediatric O
patients O
treated O
with O
Enbrel O
developed O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
during O
the O
first O
3 O
months O
of O
treatment O
. O

All O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
described O
as O
mild O
to O
moderate O
( O
erythema O
, O
itching O
, O
pain O
, O
swelling O
, O
bleeding O
, O
bruising O
) O
and O
generally O
did O
not O
necessitate O
drug O
discontinuation O
. O

Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
generally O
occurred O
in O
the O
first O
month O
and O
subsequently O
decreased O
in O
frequency O
. O

The O
mean O
duration O
of O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
3 O
to O
5 O
days O
. O

Seven O
percent O
of O
patients O
experienced O
redness B-OSE_Labeled_AE
at I-OSE_Labeled_AE
a I-OSE_Labeled_AE
previous I-OSE_Labeled_AE
injection I-OSE_Labeled_AE
site I-OSE_Labeled_AE
when O
subsequent O
injections O
were O
given O
. O

Other O
Adverse O
Reactions O
Table O
3 O
summarizes O
adverse O
reactions O
reported O
in O
adult O
RA B-Not_AE_Candidate
patients O
. O

The O
types O
of O
adverse O
reactions O
seen O
in O
patients O
with O
PsA B-Not_AE_Candidate
or O
AS B-Not_AE_Candidate
were O
similar O
to O
the O
types O
of O
adverse O
reactions O
seen O
in O
patients O
with O
RA B-Not_AE_Candidate
. O

Table O
3 O
. O

Percent O
of O
Adult O
RA O
Patients O
Experiencing O
Adverse O
Reactions O
in O
Controlled O
Clinical O
Trials O
Placebo O
Controlled O
a O
( O
Studies O
I O
, O
II O
, O
and O
a O
Phase O
2 O
S O
tudy O
) O
Active O
Controlled O
b O
( O
Study O
III O
) O
Placebo O
( O
N O
= O
152 O
) O
E O
nbrel O
c O
( O
N O
= O
349 O
) O
MTX O
( O
N O
= O
217 O
) O
E O
nbrel O
c O
( O
N O
= O
415 O
) O
Reaction O
Percent O
of O
Patients O
Percent O
of O
Patients O
Infection B-OSE_Labeled_AE
d O
( O
total O
) O
39 O
50 O
86 O
81 O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Infections I-OSE_Labeled_AE
e O
30 O
38 O
70 O
65 O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Infections I-OSE_Labeled_AE
15 O
21 O
59 O
54 O
Injection B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
11 O
37 O
18 O
43 O
Diarrhea B-OSE_Labeled_AE
9 O
8 O
16 O
16 O
Rash B-OSE_Labeled_AE
2 O
3 O
19 O
13 O
Pruritus B-OSE_Labeled_AE
1 O
2 O
5 O
5 O
Pyrexia B-OSE_Labeled_AE
- O
3 O
4 O
2 O
Urticaria B-OSE_Labeled_AE
1 O
- O
4 O
2 O
Hypersensitivity B-OSE_Labeled_AE
- O
- O
1 O
1 O
a O
Includes O
data O
from O
the O
6-month O
study O
in O
which O
patients O
received O
concurrent O
MTX O
therapy O
in O
both O
arms O
. O

b O
Study O
duration O
of O
2 O
years O
. O

c O
Any O
dose O
. O

d O
Includes O
bacterial B-OSE_Labeled_AE
, O
viral O
and O
fungal O
infections I-OSE_Labeled_AE
. O

e O
Most O
frequent O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Infections I-OSE_Labeled_AE
were O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
and O
influenza B-OSE_Labeled_AE
. O

In O
placebo-controlled O
adult O
PsO B-Not_AE_Candidate
trials O
, O
the O
percentages O
of O
patients O
reporting O
adverse O
reactions O
in O
the O
50 O
mg O
twice O
a O
week O
dose O
group O
were O
similar O
to O
those O
observed O
in O
the O
25 O
mg O
twice O
a O
week O
dose O
group O
or O
placebo O
group O
. O

Table O
4 O
summarizes O
adverse O
reactions O
reported O
in O
adult O
PsO B-Not_AE_Candidate
patients O
from O
Studies O
I O
and O
II O
. O

Table O
4 O
. O

Percent O
of O
Adult O
PsO O
Patients O
Experiencing O
Adverse O
Reactions O
in O
Placebo-Controlled O
Portions O
of O
Clinical O
Trials O
( O
Studies O
I O
& O
II O
) O
Placebo O
( O
N O
= O
359 O
) O
Enbrel O
a O
( O
N O
= O
876 O
) O
Reaction O
Percent O
of O
Patients O
Infection B-NonOSE_AE
b O
( O
total O
) O
28 O
27 O
Non B-NonOSE_AE
- I-NonOSE_AE
upper I-NonOSE_AE
Respiratory I-NonOSE_AE
Infections I-NonOSE_AE
14 O
12 O
Upper B-NonOSE_AE
Respiratory I-NonOSE_AE
Infections I-NonOSE_AE
c O
17 O
17 O
Injection B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
6 O
15 O
Diarrhea B-OSE_Labeled_AE
2 O
3 O
Rash B-NonOSE_AE
1 O
1 O
Pruritus B-NonOSE_AE
2 O
1 O
Urticaria B-OSE_Labeled_AE
- O
1 O
Hypersensitivity B-OSE_Labeled_AE
- O
1 O
Pyrexia B-NonOSE_AE
1 O
- O
a O
Includes O
25 O
mg O
subcutaneous O
( O
SC O
) O
once O
weekly O
( O
QW O
) O
, O
25 O
mg O
SC O
twice O
weekly O
( O
BIW O
) O
, O
50 O
mg O
SC O
QW O
, O
and O
50 O
mg O
SC O
BIW O
doses O
. O

b O
Includes O
bacterial B-NonOSE_AE
, O
viral O
and O
fungal O
infections I-NonOSE_AE
. O

c O
Most O
frequent O
Upper B-NonOSE_AE
Respiratory I-NonOSE_AE
Infections I-NonOSE_AE
were O
upper B-NonOSE_AE
respiratory I-NonOSE_AE
tract I-NonOSE_AE
infection I-NonOSE_AE
, O
nasopharyngitis B-NonOSE_AE
and O
sinusitis B-NonOSE_AE
. O

6.2 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

The O
detection O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( I-NonOSE_AE
including I-NonOSE_AE
neutralizing I-NonOSE_AE
antibody I-NonOSE_AE
) I-NonOSE_AE
positivity I-NonOSE_AE
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
etanercept I-NonOSE_AE
in O
the O
studies O
described O
below O
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
in O
other O
studies O
or O
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

Immunogenicity O
Patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
or O
PsO B-Not_AE_Candidate
were O
tested O
at O
multiple O
time O
points O
for O
antibodies B-NonOSE_AE
to I-NonOSE_AE
etanercept I-NonOSE_AE
. O

Antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
TNF I-OSE_Labeled_AE
receptor I-OSE_Labeled_AE
portion I-OSE_Labeled_AE
or I-OSE_Labeled_AE
other I-OSE_Labeled_AE
protein I-OSE_Labeled_AE
components I-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
Enbrel I-OSE_Labeled_AE
drug O
product O
were O
detected O
at O
least O
once O
in O
sera O
of O
approximately O
6 O
% O
of O
adult O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
or O
PsO B-Not_AE_Candidate
. O

These O
antibodies B-OSE_Labeled_AE
were I-OSE_Labeled_AE
all I-OSE_Labeled_AE
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
neutralizing I-OSE_Labeled_AE
. O

Results O
from O
JIA B-Not_AE_Candidate
patients O
were O
similar O
to O
those O
seen O
in O
adult O
RA B-Not_AE_Candidate
patients O
treated O
with O
Enbrel O
. O

In O
adult O
PsO B-Not_AE_Candidate
studies O
that O
evaluated O
the O
exposure O
of O
etanercept O
for O
up O
to O
120 O
weeks O
, O
the O
percentage O
of O
patients O
testing B-OSE_Labeled_AE
positive I-OSE_Labeled_AE
at O
the O
assessed O
time O
points O
of O
24 O
, O
48 O
, O
72 O
and O
96 O
weeks O
ranged O
from O
3.6 O
% O
-8.7 O
% O
and O
were O
all O
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
neutralizing I-OSE_Labeled_AE
. O

The O
percentage O
of O
patients O
testing O
positive O
increased O
with O
an O
increase O
in O
the O
duration O
of O
study O
; O
however O
, O
the O
clinical O
significance O
of O
this O
finding O
is O
unknown O
. O

No O
apparent O
correlation O
of O
antibody B-NonOSE_AE
development I-NonOSE_AE
to O
clinical O
response O
or O
adverse O
events O
was O
observed O
. O

The O
immunogenicity B-NonOSE_AE
data O
of O
Enbrel O
beyond O
120 O
weeks O
of O
exposure O
are O
unknown O
. O

In O
pediatric O
PsO B-Not_AE_Candidate
studies O
, O
approximately O
10 O
% O
of O
subjects O
developed O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
etanercept I-OSE_Labeled_AE
by O
Week O
48 O
and O
approximately O
16 O
% O
of O
subjects O
developed O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
etanercept I-OSE_Labeled_AE
by O
Week O
264 O
. O

All O
of O
these O
antibodies B-OSE_Labeled_AE
were I-OSE_Labeled_AE
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
neutralizing I-OSE_Labeled_AE
. O

However O
, O
because O
of O
the O
limitations O
of O
the O
immunogenicity B-NonOSE_AE
assays O
, O
the O
incidence O
of O
binding O
and O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
may O
not O
have O
been O
reliably O
determined O
. O

The O
data O
reflect O
the O
percentage O
of O
patients O
whose O
test O
results O
were O
considered O
positive B-NonOSE_AE
for I-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
etanercept I-NonOSE_AE
in O
an O
ELISA O
assay O
, O
and O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Autoantibodies O
Patients O
with O
RA B-Not_AE_Candidate
had O
serum O
samples O
tested O
for O
autoantibodies B-NonOSE_AE
at O
multiple O
time O
points O
. O

In O
RA B-Not_AE_Candidate
Studies O
I O
and O
II O
, O
the O
percentage O
of O
patients O
evaluated O
for O
antinuclear B-NonOSE_AE
antibodies I-NonOSE_AE
( I-NonOSE_AE
ANA I-NonOSE_AE
) O
who O
developed O
new B-OSE_Labeled_AE
positive I-OSE_Labeled_AE
ANA I-OSE_Labeled_AE
( O
titer O
> O
= O
1:40 O
) O
was O
higher O
in O
patients O
treated O
with O
Enbrel O
( O
11 O
% O
) O
than O
in O
placebo-treated O
patients O
( O
5 O
% O
) O
. O

The O
percentage O
of O
patients O
who O
developed O
new O
positive B-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
double I-OSE_Labeled_AE
- I-OSE_Labeled_AE
stranded I-OSE_Labeled_AE
DNA I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
was O
also O
higher O
by O
radioimmunoassay O
( O
15 O
% O
of O
patients O
treated O
with O
Enbrel O
compared O
to O
4 O
% O
of O
placebo-treated O
patients O
) O
and O
by O
Crithidia O
luciliae O
assay O
( O
3 O
% O
of O
patients O
treated O
with O
Enbrel O
compared O
to O
none O
of O
placebo-treated O
patients O
) O
. O

The O
proportion O
of O
patients O
treated O
with O
Enbrel O
who O
developed O
anticardiolipin B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
was O
similarly O
increased O
compared O
to O
placebo-treated O
patients O
. O

In O
RA B-Not_AE_Candidate
Study O
III O
, O
no O
pattern O
of O
increased O
autoantibody B-NonOSE_AE
development O
was O
seen O
in O
Enbrel O
patients O
compared O
to O
MTX O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
. O

6.3 O
Postmarketing O
Experience O
Adverse O
reactions O
have O
been O
reported O
during O
post O
approval O
use O
of O
Enbrel O
in O
adults O
and O
pediatric O
patients O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
Enbrel O
exposure O
. O

Adverse O
reactions O
are O
listed O
by O
body O
system O
below O
: O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
pancytopenia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
lymphadenopathy B-OSE_Labeled_AE
, O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
inflammatory B-OSE_Labeled_AE
bowel I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( O
IBD O
) O
General B-NonOSE_AE
disorders I-NonOSE_AE
: O
angioedema B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
autoimmune B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
Immune B-NonOSE_AE
disorders I-NonOSE_AE
: O
macrophage B-OSE_Labeled_AE
activation I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
systemic B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
, O
sarcoidosis B-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
lupus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
Neoplasms B-NonOSE_AE
benign I-NonOSE_AE
, I-NonOSE_AE
malignant I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
unspecified I-NonOSE_AE
: O
melanoma B-OSE_Labeled_AE
and O
non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
melanoma I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
, O
Merkel B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
convulsions B-OSE_Labeled_AE
, O
multiple B-OSE_Labeled_AE
sclerosis I-OSE_Labeled_AE
, O
demyelination B-OSE_Labeled_AE
, O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
transverse B-OSE_Labeled_AE
myelitis I-OSE_Labeled_AE
, O
paresthesias B-OSE_Labeled_AE
[ O
see O
Warning O
s O
and O
Precaution O
s O
( O
5.2 O
) O
] O
Ocular B-NonOSE_AE
disorders I-NonOSE_AE
: O
uveitis B-OSE_Labeled_AE
, O
scleritis B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
cutaneous B-OSE_Labeled_AE
lupus I-OSE_Labeled_AE
erythematosus I-OSE_Labeled_AE
, O
cutaneous B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
( O
including O
leukocytoclastic B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
) O
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
subcutaneous B-OSE_Labeled_AE
nodule I-OSE_Labeled_AE
, O
new O
or O
worsening O
psoriasis B-OSE_Labeled_AE
( O
all O
sub-types O
including O
pustular O
and O
palmoplantar O
) O
Opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
including O
atypical B-OSE_Labeled_AE
mycobacterial I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
aspergillosis B-OSE_Labeled_AE
and O
Pneumocystis B-OSE_Labeled_AE
jiroveci I-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
, O
and O
protozoal B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
have O
also O
been O
reported O
in O
postmarketing O
use O
. O

Rare O
( O
< O
0.1 O
% O
) O
cases O
of O
IBD B-OSE_Labeled_AE
have O
been O
reported O
in O
JIA B-Not_AE_Candidate
patients O
receiving O
Enbrel O
, O
which O
is O
not O
effective O
for O
the O
treatment O
of O
IBD B-Not_AE_Candidate
. O

